Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Specialty & Advanced Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Dec 23, 2020 18:08 ET
Knight Announces Filing of Final Base Shelf Prospectus
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) today has filed and has obtained a receipt for a (final) short form base shelf prospectus (the “Shelf Prospectus”). The Shelf Prospectus was filed with the securities regulatory authorities in each of...
Read full article
Dec 11, 2020 16:15 ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
TORONTO, Dec. 11, 2020 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, December 21, 2020:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.69
--
--
Price to Sales - TTM
3.83
3.53
12.51
Price to Book - most recent quarter
0.79
0.79
4.00
Price to Cash Flow per share - TTM
15.28
15.28
16.26
Price to Free Cash Flow per share - TTM
--
--
27.60
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 20203,065,666-1,577,280
Dec 15, 20204,642,946307,420
Nov 30, 20204,335,526408,254
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company's products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.

See business summary

 

Twitter

Search (past week) for $GUD.CA